457 related articles for article (PubMed ID: 17240528)
1. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
2. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
[TBL] [Abstract][Full Text] [Related]
3. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
5. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
6. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
Stephenson AJ; Kattan MW; Eastham JA; Dotan ZA; Bianco FJ; Lilja H; Scardino PT
J Clin Oncol; 2006 Aug; 24(24):3973-8. PubMed ID: 16921049
[TBL] [Abstract][Full Text] [Related]
7. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
8. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
9. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
10. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
11. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Sandler HM; Eisenberger MA
J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
[TBL] [Abstract][Full Text] [Related]
12. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
Naito S
Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
[TBL] [Abstract][Full Text] [Related]
14. Salvage options for biochemical recurrence after primary therapy for prostate cancer.
Bong GW; Keane TE
Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
16. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
17. Perineal salvage prostatectomy for radiation resistant prostate cancer.
van der Poel HG; Beetsma DB; van Boven H; Horenblas S
Eur Urol; 2007 Jun; 51(6):1565-71; discussion 1572. PubMed ID: 16949728
[TBL] [Abstract][Full Text] [Related]
18. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
[TBL] [Abstract][Full Text] [Related]
19. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Slawin KM
Nat Clin Pract Urol; 2004 Dec; 1(2):90-6. PubMed ID: 16474521
[TBL] [Abstract][Full Text] [Related]
20. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
